Identification of colon-tumor-associated antigens by T-cell lines derived from tumor-infiltrating lymphocytes and peripheral-blood lymphocytes from patients immunized with an autologous tumor-cell/bacillus calmette-Guérin vaccine

✍ Scribed by Janet H. Ransom; Barbara A. Pelle; Henk Hubers; Linette M. Keynton; Michael G. Hanna; Nicholas Pomato

• Publisher: John Wiley and Sons
• Year: 1993
• Tongue: French
• Weight: 953 KB
• Volume: 54
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/ijc.2910540505

✦ Synopsis

Abstract

Tumor immunity developing as a response to an autologous colon‐tumor/bacillus Calmette‐Guerin (BCG) vaccine appears to be associated with induction of CD4 helper T cells, implied by the observation that vaccine efficacy is associated with major histocompatibility complex class‐ll molecule expression on the vaccine tumor cells. Therefore, in an attempt to identify colon‐tumor‐associated antigens responsible for conferring immunity, we examined and compared the proliferative responses of peripheral‐blood lymphocytes (PBL) from patients immunized with the autologous tumor/BCG vaccine to T‐cell lines cloned expanded from colon‐tumor‐infiltrating lymphocytes to 5 antigens isolated on the basis of their reactivity by colon‐tumor‐reactive human monoclonal antibodies. Enzymatically dissociated colon tumors provided a source for establishment of cloned T‐cell lines, tumor cell lines propagated in vitro or in vivo as nude‐mouse xenografts and EBV‐transformed B‐cell lines used as antigen‐presenting cells. Of 104 different T‐cell lines tested, only 3 proliferated in response to CTAA 28A32‐46K, and I to the CTAA28A32‐32K antigen. In contrast, PBL from 64% of patients immunized with the autologous colon‐tumor/BCG vaccine responded to the CTAA 28A32‐32K antigen. This antigen is related to a family of calcium‐ and phospholipid‐binding placental proteins termed annexins. Since proliferative responses developed to this antigen after vaccination in 64% of individuals, this antigen may be an important common colon‐tumor‐associated rejection antigen.